Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. - Wikidata - awgldk - TriplyDB

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.

http://www.wikidata.org/entity/Q33434817

about

Triplet combinations in relapsed/refractory myeloma: update on recent phase 3 trials.A look backward and forward in the regulatory and treatment history of multiple myeloma: Approval of novel-novel agents, new drug development, and longer patient survival.Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma.Pomalidomide, Bortezomib and Dexamethasone (PVD) for Patients with Relapsed, Lenalidomide Refractory Multiple Myeloma.Immunotherapy in hematologic malignancies: past, present, and future.PDK1 inhibitor GSK2334470 exerts antitumor activity in multiple myeloma and forms a novel multitargeted combination with dual mTORC1/C2 inhibitor PP242 Interferon-alpha-based immunotherapies in the treatment of B cell-derived hematologic neoplasms in today's treat-to-target era Cutting edge genomics reveal new insights into tumour development, disease progression and therapeutic impacts in multiple myeloma.Carfilzomib boosted combination therapy for relapsed multiple myeloma Highlights from the 58th meeting of the American Society of Haematology, 1-6 December 2016, San Diego, USA.Retreatment and Prolonged Therapy with Subcutaneous Bortezomib in Patients with Relapsed Multiple Myeloma: A Randomized, Controlled, Phase III Study.New developments in the management of relapsed/refractory multiple myeloma - the role of ixazomib.Pomalidomide-dexamethasone in refractory multiple myeloma: Long-term follow-up of a multi-cohort phase II clinical trial.Managing multiple myeloma in elderly patients.Novel Immunotherapies for Multiple Myeloma.Overcoming multiple myeloma drug resistance in the era of cancer 'omics'.Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma.The potential of ixazomib, a second-generation proteasome inhibitor, in the treatment of multiple myeloma.Novel investigational drugs active as single agents in multiple myeloma.Immunologic approaches for the treatment of multiple myeloma.CIK Cells and HDAC Inhibitors in Multiple Myeloma.Which therapies will move to the front line for multiple myeloma?Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes.Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions.An update on the role of daratumumab in the treatment of multiple myeloma.Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma.How is patient care for multiple myeloma advancing?Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.The safety of daratumumab for the treatment of multiple myeloma.A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma.New developments in the treatment of multiple myeloma - clinical utility of daratumumab.Daratumumab for the treatment of multiple myeloma.Monoclonal antibody therapy in multiple myeloma.Next-generation multiple myeloma treatment: a pharmacoeconomic perspective.Daratumumab, Elotuzumab, and the Development of Therapeutic Monoclonal Antibodies in Multiple Myeloma.Second primary malignancies in multiple myeloma: an overview and IMWG consensus.Management of adverse events induced by next-generation immunomodulatory drug and proteasome inhibitors in multiple myeloma.Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis.Is immunotherapy here to stay in multiple myeloma?Bone marrow micro-environment is a crucial player for myelomagenesis and disease progression.

P2860

Q30238893-3C1C9F62-3FA0-4F01-B092-80ACDFC21BE4 Q30239781-139D492A-D998-411F-8966-DE917383A701 Q33441476-EEBB11A3-95BC-442C-AF60-C743F042949E Q33443411-36DFDB93-1CFC-4D34-860C-F0FB65FED480 Q33593865-7773A8CD-1968-4F8B-8F62-0920708574DA Q33889132-973E7988-F728-42F3-9EF9-AD1AC26976F9 Q33909086-64A8DBBB-AD17-41C5-B65A-296D63DB03BA Q34556156-475BE680-C539-4791-9D77-232946DFC622 Q37652953-CC17A2EC-7DD6-4C94-85B2-5913494EF80D Q37720728-E64B6511-336A-42F5-BD56-684D4CCC804A Q38372319-0E59D823-8BD3-45D0-A90B-5AFB9D707645 Q38598891-5F3CDA0A-7EAB-4F9C-9552-F333E309DF75 Q38599023-43837A0B-8D1B-490C-A4EA-3F21408B8A7D Q38605484-653B48C4-581F-43FB-B97F-FC031001A08F Q38640444-75DE824F-9873-4CEE-9527-2733810D611E Q38671390-D14278C8-08B1-4897-B704-ECDE1EAEE5F9 Q38672091-51D0B5F3-4D1A-44A6-B952-1F72D5B4C30D Q38685108-9E4F841F-DF7B-4F4D-91FF-1387E04AB992 Q38690290-393B2045-969E-43B5-8C2C-557C97197E78 Q38692244-8241F95A-6187-4FF6-841E-141F0BBCD473 Q38705046-58C3CDF9-0440-4D30-B405-1722B97FB60E Q38733592-C6068E15-7FED-45AD-B929-840E4308923E Q38756800-99E8A161-0FD7-49BB-826E-A1713DBBAE23 Q38757067-853930E2-C419-47DE-9F92-C75100DF70AC Q38775700-DCC0BE64-6D3D-45B1-AF86-42C26B91DE23 Q38780843-6434F5E9-CA0E-49D5-B6A1-BE54B12B51BA Q38786149-6A74D7B5-7E5B-40E7-83F0-ADA739EB8B56 Q38792725-FE79DAE6-1D12-4B8B-91A2-987D5352672C Q38793959-2C8460A2-F26C-4E7B-AA24-EF0C95BDA5DE Q38797097-8E692DB7-91F8-46FF-A613-55CD0286B064 Q38820002-2941EBF6-9757-4E1F-AD27-8063B59B34E1 Q38824538-E7CC6D2F-3456-4C12-93EE-874830828F5A Q38956372-ACB37CE9-5F0A-41E3-8138-EE8F65C558AF Q38981247-726074EB-3CBB-4A14-8BF6-5ECF6D69C7D3 Q38996881-5D369C53-51DF-4FC5-932D-46C80DBBCBAE Q39013620-ACC7282B-AFB1-4B02-A7EC-737EC868AD98 Q39022303-C3BC46FD-9A03-4E93-B76C-78AC81A6BB17 Q39070193-CF4BE2E7-8974-4E8F-8BB4-A861C653700F Q39084427-AF89C0C5-04A5-42D9-BEE1-305C330ADE15 Q39093915-9A6599CB-E3D8-4DD2-A73E-EE81E67F5AF5

P2860

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.

http://www.wikidata.org/entity/Q33434817

description

2016 nî lūn-bûn

@nan

2016 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.

@ast

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.

@en

type

label

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.

@ast

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.

@en

prefLabel

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.

@ast

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.

@en

P1433

Q33434817-3440758D-71A7-48BD-8F76-03DCF925C853

P1476

Q33434817-433076A7-7586-4CBB-B654-78ABF564555D

P2093

Q33434817-01F07BA9-6ADC-41BF-953F-029940B32C22

Q33434817-02EF5AEC-E9D5-4797-9493-283A8A220651

Q33434817-28AD2027-F471-4415-A891-65FF5AF7C190

Q33434817-3BB43653-5835-4B72-9849-7434EBA17033

Q33434817-3F6809A9-D57F-41C9-A01A-0EE803365E19

Q33434817-40D0E380-7F1E-41A5-A926-FA60F6B874B5

Q33434817-4F5F6068-07CD-44AD-876A-0B2251145C95

Q33434817-540F4CA7-B71F-4ECF-B7A9-D9B07664A6D6

Q33434817-7A390027-076D-45E4-A91D-8126B13BF541

Q33434817-8DC27457-69FA-457B-B70A-5E2750B7AF33

P304

Q33434817-3E1EBAAB-4D75-4CEC-B55B-4D06ACE996C6

P31

Q33434817-E7A891A7-5ADC-4F99-9CBB-C5B32BB9835F

P356

Q33434817-B0367E0E-E2D1-4AB0-A3B0-AF7A54222274

P407

Q33434817-20840AEF-FD48-4CD2-B8FC-6875AF151C34

P433

Q33434817-36E8E91F-1B01-438B-8ECC-8DEC3229FD01

P478

Q33434817-10D3D5C7-B6ED-4768-9A08-46DAC109C821

P50

Q33434817-52CBD0CE-FE18-4DC1-9075-D79A8FF2FB4A

Q33434817-768E9EB2-4AAE-447D-BACF-87D7454B755D

Q33434817-D6CE6C14-440E-4E39-9BA4-0CF8E51564E4

Q33434817-EE9976E5-78D1-4E4B-8A38-F14848EE0BE2

Q33434817-F9D0E5E2-3749-45EF-AE17-F1F8FE7274C3

P577

Q33434817-86E5397F-182C-4426-94A9-4C621E10C7C5

P698

Q33434817-74698E38-E625-4D8F-88D4-110A90B1440A

P921

Q33434817-7F5562DE-FB9C-421E-95F7-A1B82AB45341

P356

P1433

The New England Journal of Medicine

P1476

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.

@en

P2093

Ajay K Nooka

http://www.w3.org/2001/XMLSchema#string

Andrew Spencer

http://www.w3.org/2001/XMLSchema#string

Asher Chanan-Khan

http://www.w3.org/2001/XMLSchema#string

CASTOR Investigators

http://www.w3.org/2001/XMLSchema#string

Himal Amin

http://www.w3.org/2001/XMLSchema#string

Jordan Schecter

http://www.w3.org/2001/XMLSchema#string

Maria V Mateos

http://www.w3.org/2001/XMLSchema#string

Markus Munder

http://www.w3.org/2001/XMLSchema#string

Meral Beksac

http://www.w3.org/2001/XMLSchema#string

Ming Qi

http://www.w3.org/2001/XMLSchema#string

P304

754-766

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1606038

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

375

http://www.w3.org/2001/XMLSchema#string

P50

Pieter Sonneveld

Antonio Palumbo

P577

2016-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27557302

http://www.w3.org/2001/XMLSchema#string

P921